4basebioLSE:4BB -0.95%61 Market Cap is £80.52 Mil as of Jul. 01, 2026. GuruFocus rates LSE:4BB with a GF Score™ of 61/100 and a GF Value™ of £28.26 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,428 Biotechnology companies, 4basebio ranks worse than 51.19% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). 4basebio's share price for the quarter that ended in Dec. 2025 was £6.15. 4basebio's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 15.49 Mil. Therefore, 4basebio's market cap for the quarter that ended in Dec. 2025 was £95.23 Mil.
4basebio's quarterly market cap
declined
from Dec. 2024 (£187.21 Mil) to Jun. 2025 (£152.53 Mil) and
declined
from Jun. 2025 (£152.53 Mil) to Dec. 2025 (£95.23 Mil).
4basebio's annual market cap
increased
from Dec. 2023 (£83.77 Mil) to Dec. 2024 (£187.21 Mil) but then
declined
from Dec. 2024 (£187.21 Mil) to Dec. 2025 (£95.23 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. 4basebio's Enterprise Value for Today is £79.44 Mil.
4basebio (LSE:4BB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
4basebio Market Cap Related Terms
4basebio Market Cap Historical Data
* Premium members only.
The historical data trend for 4basebio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:4BB vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, 4basebio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4basebio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4basebio's Market Cap distribution charts can be found below:
* The bar in red indicates where 4basebio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
4basebio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4basebio (LSE:4BB) has a Market Cap of £80.52 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on 4basebio and its competitors. According to the industry distribution chart, 4basebio ranks #731 out of 1428 companies in the Biotechnology industry, placing it in the top 51.2%.
Is 4basebio's Market Cap too high?
4basebio's current Market Cap is £80.52 Mil. Based on the distribution chart, 4basebio ranks #731 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 4basebio has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 4basebio ranks #731 out of 1428 companies for Market Cap. This places 4basebio in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on 4basebio and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4basebio's current Market Cap is £80.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (LSE:4BB) is currently considered Possible Value Trap. The stock's GF Value™ is £28.26, compared to a current price of £5.20 — trading 81.6% below its estimated fair value. The current Market Cap is £80.52 Mil. 4basebio's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For 4basebio (LSE:4BB), the current Market Cap is £80.52 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4basebio (LSE:4BB) Overvalued in 2026?
Based on GuruFocus' analysis, 4basebio stock appears to be undervalued.
The current stock price of £5.20 is trading 81.6% below its estimated GF Value™ of £28.26.
GuruFocus considers 4basebio to be Possible Value Trap.
Key valuation signals for LSE:4BB:
Market Cap: £80.52 Mil
GF Value™: £28.26 vs. price of £5.20 (81.6% below fair value)
No single metric tells the full story. See the LSE:4BB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
61GF Score
Get the complete analysis for LSE:4BB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:4BB has been successfully added to your 
